Athenex Inc logo

ATNX

Athenex Inc

$0.49

Earnings Summary

Revenue
$0.03Mn
Net Profits
$-0.03Mn
Net Profit Margins
-102.03%

Highlights

Revenue:

Athenex Inc’s revenue fell -99.86% since last year same period to $0.03Mn in the Q2 2022. On a quarterly growth basis, Athenex Inc has generated -99.89% fall in its revenue since last 3-months.

Net Profits:

Athenex Inc’s net profit jumped 99.91% since last year same period to $-0.03Mn in the Q2 2022. On a quarterly growth basis, Athenex Inc has generated 99.82% jump in its net profits since last 3-months.

Net Profit Margins:

Athenex Inc’s net profit margin jumped 34.74% since last year same period to -102.03% in the Q2 2022. On a quarterly growth basis, Athenex Inc has generated -74.1% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Athenex Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.15
EPS Estimate Current Year
-0.15

Highlights

EPS Estimate Current Quarter:

Athenex Inc’s earning per share (EPS) estimates for the current quarter stand at -0.15 - a 0% jump from last quarter’s estimates.

EPS Estimate Current Year:

Athenex Inc’s earning per share (EPS) estimates for the current year stand at -0.15.

Key Ratios

Key ratios of the Athenex Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.28
Return on Assets (ROA)
-0.21
Return on Equity (ROE)
-2.37
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Athenex Inc’s earning per share (EPS) jumped 15.15% since last year same period to -0.28 in the Q2 2022. This indicates that the Athenex Inc has generated 15.15% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Athenex Inc’s return on assets (ROA) stands at -0.21.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Athenex Inc’s return on equity (ROE) stands at -2.37.

Dividend Per Share (DPS):

Athenex Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-0.19
-0.16
15.79%
2022-07-29
-0.15
-0.28
-86.67%

Company Information

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Company's current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex's employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; multiple locations in Chongqing, China; Manchester, UK; Guatemala City, Guatemala and Buenos Aires, Argentina.

Organisation
Athenex Inc
Headquarters
Buffalo, New York, US
Employees
599
Industry
Health Technology
CEO
Johnson Lau